JANSSEN PHARMACEUTICA N V-COMPANY INSIGHT - LIFE SCIENCE ANALYTICS - 2008/05/26 - TF Market Research

Report title: JANSSEN PHARMACEUTICA N V-COMPANY INSIGHT

from TF Market Research
42 page report published May 26, 2008

Price $1,640.00 available for immediate download
This report is also available for purchase on a per-page basis.

Report Overview

Purchase by Section

Search Inside

About TF Market Research

...Turnhoutseweg ##, B-#### Beerse, Belgium email: info@janbe.jnj.com Website: http://www.janssenpharmaceutica.be phone: ##-##-##-##-## ...

Source:

LIFE SCIENCE ANALYTICS

Author:

HARINATHA, G.

Company:

JANSSEN PHARMACEUTICA N.V.

Geographic Regions:

BELGIUM, EUROPE, WESTERN EUROPE

Non-Billable Page Numbers:

Format:

PDF

Sections
	Title	Starting Page	Number of Pages
	Company Information	1	1
	Janssen Pharmaceutica N V [NonUS -- Symbol : Private]	1	1
	Formation Date: 1953	1	1
	Business Summary	1	1
	Product Glance	3	1
	Diseasehub Classification	3	1
	Product Summary	4	2
	Partner	5	1
	Product Details	5	1
	1. Cilest Disease Hub Description	5	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 2. Daktarin Description	5	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 3. Durogesic Description	5	1
	Therapeutic	5	1
	Drug Class Current Trial Trial Details Last Updated 4. Procrit Description	6	1
	Therapeutic Drug Class Current Trial Trial Details	6	1
	Last Updated Partnering	6	1
	Details	7	1
	5. Haldol Description	7	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 6. Imodium Description	7	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 7. Leustatin Description	7	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 9. Motilium Description	7	1
	Therapeutic Drug Class	7	1
	Current Trial Trial Details Last Updated 10. Nizoral Description	8	1
	Therapeutic Transplant Current Trial M Trial Details Presently Last Updated 4/16/2007 12. Pariet (rabeprazole) Digestive De	8	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 13. Reasec Description	8	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 14. Regranex Description	8	1
	Therapeutic Current Trial Trial Details Last Updated 15. Reminyl	8	1
	Description	9	3
	Therapeutic Drug Class Current Trial Trial Details Last Updated Partnering Details	9	2
	16. Risperdal Description	9	1
	17. Sporanox (itraconazole) Infections Description Sporanox	9	1
	Therapeutic Fungal Drug Class Antifungals Current Trial M Trial Details Presently Last Updated 10/9/2006 18. Sufenta (sufent	9	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 19. Systen Description	10	1
	22. Vermox (mebendazole) Infections	10	1
	Therapeutic Drug Class Current Trial M Trial Details Last Updated 23. Gyno-Daktarin Description Gyno	11	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 24. Ovysmen Description	11	1
	Therapeutic Drug Class Current Trial Trial Details Last Updated 25. Trinovum Description	11	1
	Therapeutic Current Trial Trial Details Last Updated 27. Invega Description	11	1
	Therapeutic Current Trial Trial Details	12	2
	Last Updated 5/8/2008 28. Risperdal Consta Central Description Risperdal	14	1
	Therapeutic Drug Class Current Trial Trial Details	14	2
	Last Updated Partnering Details	15	2
	29. VX950 Description	15	1
	30. Fentanyl TAIFUN Cancer Description Fentanyl	16	1
	Therapeutic Drug Class Current Trial Trial Details	17	1
	Last Updated Partnering Details	18	2
	31. GlyT-1 JANSSEN PHARMA Central Nervous	18	1
	Description	19	1
	Therapeutic Current Trial Trial Details	19	1
	32. GlyT-1 JANSSEN PHARMA Central Nervous Description Glycine reuptake	19	1
	33. Avicidin Description	19	1
	Therapeutic Current Trial	19	1
	Trial Details	20	1
	Last Updated 34. R207910 Description	20	1
	Therapeutic Drug Class Current Trial Trial Details	20	1
	Last Updated 35. Avicidin	20	1
	Description	21	1
	Therapeutic Current Trial Trial Details	21	1
	Last Updated 36. Avicidin Description	21	1
	Last Updated 37. Avicidin Description	21	1
	Therapeutic	21	1
	Current Trial Trial Details	22	1
	Last Updated	22	1
	Recent Financings	23	1
	Corporate Partners	23	1
	Deal Category: Miscellaneous Date	23	1
	Deal Value (in $ MM)	23	7
	Partner	24	1
	Date	24	1
	Deal Category: Product Date	24	1
	Date	29	1
	Partner	29	3
	Deal Category: Technology Date	29	1
	Recent Updates	32	1
	Company Announcements	32	1
	9/20/2007 -- Janssen Pharmaceutica reorganizes its Belgian activities	32	1
	11/13/2006 -- Janssen Pharmaceutica Builds New Plant	32	1
	9/29/2006 -- Janssen Pharmaceutica Gives "Partnership Award" to Eight Suppliers of Chemical Production	32	1
	9/12/2006 -- RNAi Pioneer Craig Mello Named Inaugural Winner	32	1
	6/25/2006 -- Prezista Approved by FDA in the US! An Unusual Achievement that Everyone can be proud of	32	1
	Time in Six s	33	1
	1/30/2006 -- Janssen Pharmaceutica Finalist in Facility of the Competition-2006	33	1
	1/5/2006 -- Xian-Janssen Selected as Employer of the in China	33	1
	11/25/2005 -- Quality Manager of the : Ben Barbe of Janssen Pharmaceutica	33	1
	10/24/2005 -- The Xian-Janssen Joint Venture Fetes Its 20 s	33	1
	10/17/2005 -- Janssen Pharmaceutica achieves Kyoto target in 2005 and switches over to green energy company-wide	33	1
	10/2/2005 -- Business Open Day at Janssen Pharmaceutica	33	1
	6/20/2005 -- The Greatest Belgian	34	1
	3/14/2005 -- Johnson Johnson inaugurated the Drug Safety Evaluation Center in Beerse	34	1
	3/8/2005 -- For the fifth time running, Janssen Pharmaceutica has been ranked among the Top 3 Most Attractive Employers in Be	34	1
	1/12/2005 -- Ajit Shetty, Manager of the 2004	34	1
	12/7/2004 -- King Albert Makes a Working Visit	34	1
	10/27/2004 -- Opening of the Dr Paul Janssen Research Center	34	1
	10/7/2004 -- Janssen Pharmaceutica donates 10,000 euros to the Association of Parents of Children Killed in Road Accidents	34	1
	12/5/2003 -- Janssen Pharmaceutica Initiates Ambitious Diversity Policy	35	1
	12/1/2003 -- Janssen Pharmaceutica Geel wins ergonomics award	35	1
	10/24/2003 -- Janssen Pharmaceutica Saves Energy	35	1
	5/14/2003 -- Opening Clinical Pharmacology Unit	35	1
	3/12/2003 -- Minister-President Patrick Dewael Lays Foundation Stone of New Building at Janssen Pharmaceutica	35	1
	10/8/2002 -- Scientists elect Johnson Johnson as third most attractive employer in the world	35	1
	9/20/2002 -- Janssen Pharmaceutica Goes for Public Transportation	35	1
	5/22/2002 -- Beerse 2 is biggest computer- and telecomcenter for JJ-group in Europe	36	1
	4/15/2002 -- Investing in research: patients are Worth the Risk	36	1
	4/12/2002 -- JJ in top 50 Business week	36	1
	4/4/2002 -- Janssen Pharmaceutica NV most engaging employer in Belgium	36	1
	Deals & Alliances	36	1
	4/22/2008 -- Nycomed, Janssen both ink IT outsourcing contracts	36	1
	3/31/2008 -- Sareum Ltd. Extension of Collaborationwith Johnson and Johnson Pharmaceutical R&D	36	1
	1/24/2008 -- Galapagos achieves EUR 3.4 million milestone payment from Janssen Pharmaceutica NV	37	1
	1/3/2008 -- Akela Pharma licenses Fentanyl TAIFUN to Janssen Pharmaceutica NV for Canada	37	1
	1/2/2008 -- Galapagos enters into oncology target discovery collaborationwith Janssen Pharmaceutica	37	1
	1/2/2008 -- Biovail Announces Supply Agreement for Commercialization of Extended-Release Tramadol	37	1
	10/24/2007 -- Galapagos NV signs major Arthritis deal potentially worth Up to 1 billion Euros with Janssen Pharmaceutica N.V.	37	1
	6/21/2007 -- Lab International Licenses Fentanyl Taifun To Janssen Pharmaceutica Nv For Europe	37	1
	1/11/2007 -- Kinaxo Announces Agreement with Johnson & Johnson Pharmaceutical Research & Development	38	1
	12/14/2006 -- Vertex earns $15M milestone payment	38	1
	8/20/2006 -- Co-Development and co-marketing of the Anti TNFa Monoclonal Antibody Preparation "CNTO148" (Golimumab)	38	1
	3/14/2005 -- The Archeological Survey of India and Janssen Pharmaceutica sign Memorandum	38	1
	3/10/1998 -- Akorn Acquires Two Pharmaceutical From Johnson & Johnson Division	39	1
	Intellectual Property	39	1
	3/12/2007 -- Johnson & Johnson Receives Subpoenas	39	1
	6/23/2006 -- SR Pharma plc welcomes the European Patent Office decision to limit the scope of Kreutzer-Limmer RNAi Patent cla	39	1
	Product Update	39	1
	3/31/2008 -- Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on Telaprevir	39	1
	2/12/2008 -- Pricara recalls 25 mcg/hr Duragesic (fentanyl transdermal system) CII Pain Patches	40	1
	1/7/2008 -- Vertex Pharmaceuticals Reports Progress in Development of Investigational HCV Drug Telaprevir	40	1
	9/5/2007 -- AKELA Pharma Inc. Announces Positive Results for The Extension Part of its Phase IIb Fentanyl Taifun	40	1
	3/30/2007 -- Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control	40	1
	3/9/2007 -- Ortho Biotech Revises Prescribing Information for Procrit (Epoetin alfa)	41	1
	12/19/2006 -- Alkermes Announces Submission of New Drug Application for Risperdal Consta in Japan	41	1
	12/9/2004 -- Novel Antibiotic Shows Promise in Shortening Treatment Duration of Tuberculosis	41	1
	9/1/2002 -- Risperdal Consta, a new generation of atypical antipsychotics	41	1
	4/10/2002 -- Data suggest Reminyl effectively treats dementia in patients with cerebrovascular	41	1
	disease	42	1
	Regulatory	42	1
	2/4/2008 -- Akela Pharma Receives Letter from the FDA Regarding its Pre-clinical Toxicology Studies for Fentanyl Taifun	42	1
	6/28/2007 -- Invega Receives Marketing Authorization In European Union For Treatment Of Schizophrenia	42	1
	4/27/2007 -- FDA Approves Invega (paliperidone) For Long-Term Maintenance Treatment Of Schizophrenia	42	1
	4/13/2007 -- FDA Approves New Dose of Risperdal Consta for Schizophrenia Treatment	42	1
	12/20/2006 -- Invega (paliperidone) Approved By FDA As New Treatment For Schizophrenia	42	1

Enter the keyword(s) which you would like to search for within this document and click "Search"

TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.

Price: $1,640.00

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Get FREE Research

Can't Decide?

Purchasing premium research sight unseen can be intimidating. We want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.